In This Section

Program

Please note that this special conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. The conference content will be recorded and made available as an on-demand program after the conference.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Sunday, September 15

monday, September 16

tuesday, September 17

wednesdayday, September 18

Sunday, September 15

REGISTRATION

3-8 p.m. | America Ballroom Foyer

WELCOME AND Keynote lectures

5:30-7:15 p.m. | American Ballroom Center & North | CME Eligible

  • 5:30 p.m. | Welcome from Conference Cochairs
  • 5:50 p.m. | Keynote Lecture
    Pancreas Cancer 2024: Translating genomic findings into clinical actionability
    Eileen M. O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York
  • 6:35 p.m. | Rising Star Keynote
    Targeting autophagy in pancreatic cancer
    Joseph D. Mancias, Dana-Farber Cancer Institute, Boston, Massachusetts

Lightning Presentation Session A

7:20-7:40 p.m. | American Ballroom Center & North | CME Eligible

  • 7:20 p.m. | Introduction of Lighting Presentation Speakers
    Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, Nebraska
  • 7:25 p.m. | Systemic targeting of therapeutic RNA to pancreatic ductal adenocarcinoma via a novel, cell-penetrating, and nucleic acid-binding monoclonal antibody*
    Diana Martinez-Saucedo, Yale University School of Medicine, New Haven, Connecticut
  • 7:28 p.m. | Uncovering molecular differences in pancreatic ductal adenocarcinoma tissues from Black and White patients in the US*
    Saurabh Mandal, Henry Ford Health, Detroit, Michigan
  • 7:31 p.m. | Canonical Notch signaling in cancer-associated fibroblasts supports an immunosuppressive pancreatic tumor microenvironment*
    Allison Bischoff, University of Michigan, Ann Arbor, Michigan
  • 7:34 p.m. | Phase 2 trial testing the PARP inhibitor Niraparib in patients with advanced pancreatic cancer with pathogenic variants in BRCA 1, BRCA2, PALB2, ATM, and CHEK2*
    Brandon Huffman, Dana-Farber Cancer Institute, Boston, Massachusetts

POSTER SESSION A AND OPENING RECEPTION

7:45-10 p.m. | American Ballroom South

Monday, September 16

CONTINENTAL BREAKFAST

7-8 a.m. | Essex Ballroom (3rd Floor)

Career Development Roundtable Session 1

7-8 a.m. | Essex Ballroom (3rd Floor)

Attendance to each of the Career Roundtables will be on a first-come, first-served basis and no pre-registration is required. Participants may rotate to as many tables as they like during the session, providing the opportunity to network and interact with a diverse cadre of experts.

Balancing Clinical and Research Life
Jashodeep Datta, University of Miami Miller School of Medicine, Miami, Florida		How to Get a Paper Published
Cosimo Commisso, Sanford Burnham Prebys, San Diego, California
Harmony Turk, Cancer Research, American Association for Cancer Research, Philadelphia, PA
Balancing Clinical and Research Life
Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York		How to Get a Paper Published
Teresa A. Zimmers, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon
Choosing a Career Path: Academia vs. Industry
Channing Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina		How to Write a Grant
Kirsten Bryant, University of North Carolina, Chapel Hill, North Carolina
Collaborating with Industry
Eileen M. O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York		How to Write a Grant
Marina Pasca Di Magliano, University of Michigan, Ann Arbor, Michigan
Careers in Industry
Mallika Singh, Revolution Medicines, Redwood City, California		Starting Your Lab
Joseph D. Mancias, Dana-Farber Cancer Institute, Boston, Massachusetts
Starting Your Lab
Erica D. Pratt, Boston University, Boston, Massachusetts

Plenary Session 1: Cachexia, Diet, and Metabolism

8:15-9:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Peter J. Allen, Duke University School of Medicine, Durham, North Carolina

  • 8:20 a.m. | Mechanisms of pancreatic cancer cachexia
    Teresa A. Zimmers, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon
  • 8:45 a.m. | Developing therapies for pancreatic cancer cachexia
    Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles, California
  • 9:10 a.m. | Neuroendocrine causes and effects of cachexia
    Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
  • 9:35 p.m. | Endocrine beta-cell stress promotes pancreatic ductal adenocarcinoma through endocrine-exocrine cell crosstalk*
    Cathy Garcia, Yale University, New Haven, Connecticut
  • 9:45 p.m. | Dietary fats dictate pancreatic cancer fate via phospholipid saturation*
    Christian Ruiz, Yale University, New Haven, Connecticut

break

9:55-10:30 a.m. | American Ballroom Foyer

PLENARY SESSION 2: Immunology and Immunotherapy

10:30 a.m.-12:10 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Alec C. Kimmelman, NYU Langone Health, New York, New York

  • 10:35 a.m. | The tumor-reactive CD8+ T-cell repertoire in pancreatic cancer as revealed by single-cell sequencing
    Rienk Offringa, German Cancer Research Center, Heidelberg, Germany
  • 11 a.m. | Investigating the role of CD4 T cells in the pancreatic tumor microenvironment
    Katelyn T. Byrne, Oregon Health and Science University, Portland, Oregon
  • 11:25 a.m. | Exploiting functional specialization of myeloid-derived suppressor cells to overcome therapeutic resistance in pancreatic cancer
    Jashodeep Datta, University of Miami Miller School of Medicine, Miami, Florida
  • 11:50 a.m. | Discovery and therapeutic potential of novel cryptic peptides in pancreatic cancer*
    Gurcan Gunaydin, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12 p.m. | Reprogramming and selective recruitment of distinct neutrophil subpopulations restrain cancer metastasis*
    Jae Lee, Johns Hopkins University School of Medicine, Baltimore, Maryland

lunch on own

12:10-2:30 p.m.

Plenary Session 3: Stromal Aspects of the Microenvironment and Tumor Microenvironment

2:30-4:10 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, Nebraska

  • 2:35 p.m. | Functional heterogeneity of fibroblast populations in pancreatic cancer
    Giulia Biffi, University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
  • 3 p.m. | Mechanisms and consequences of pancreatic cancer stromal evolution
    Mara Sherman, Memorial Sloan Kettering Cancer Center, New York, New York
  • 3:25 p.m. | Targeting the tumor microenvironment to improve responses to therapy
    David G. DeNardo, Washington University School of Medicine in St. Louis, St. Louis, Missouri
  • 3:50 p.m. | Temporally resolved proteomics identifies nidogen-2 as a co-target in pancreatic cancer that modulates fibrosis and therapy response*
    Paul Timpson, The Garvan Institute of Medical Research, Sydney, NSW, Australia
  • 4 p.m. | Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy*
    Max Wattenberg, University of Pennsylvania, Philadelphia, Pennsylvania

lightning presentation session b

4:15-4:35 p.m. | American Ballroom Center & North | CME Eligible

  • 4:15 p.m. | Introduction of Lighting Presentation Speakers
    Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:20 p.m. | Altered mRNA splicing mimics chromosome loss and drives pancreatic cancer*
    Natasha Pinto Medici, Yale University, New Haven, Connecticut
  • 4:23 p.m. | The circadian rhythm gene Dec2 regulates multiple components of the antigen presentation pathway to promote pancreatic cancer dormancy by immune evasion*
    Chris Harris, University of Rochester Medical Center, Rochester, New York
  • 4:26 p.m. | Disruption of sulfatide metabolism by targeting UGT8 is an actionable metabolic vulnerability for pancreatic cancer early interception*
    Riccardo Ballaro, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 4:30 p.m. | Meta-analysis of spatial transcriptomics data from pancreatic cancer precursors proposes a common molecular framework for PanIN and IPMN*
    Matthew Iyer, University of Michigan, Ann Arbor, Michigan

Poster session b/reception

4:45-7 p.m. | American Ballroom South

Tuesday, September 17

CONTINENTAL BREAKFAST

7-8 a.m. | Essex Ballroom (3rd Floor)

Plenary Session 4: KRAS Resistance, Mechanisms, and Therapeutics

8:15-9:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Alec C. Kimmelman, NYU Langone Health, New York, New York

  • 8:20 a.m. | Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer
    Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 8:45 a.m. | Adaptation and resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma
    Kenneth P. Olive, Columbia University Irving Medical Center, New York, New York
  • 9:10 a.m. | Targeting the oncogenic state of RAS with tri-complex inhibitors
    Mallika Singh, Revolution Medicines, Redwood City, California
  • 9:35 a.m. | Identifying synergistic combinations with KRAS inhibition in PDAC*
    Fredrik Thege, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 9:45 a.m. | Evaluating direct KRASQ61H inhibition in pancreatic cancer models*
    Andrew Waters, University of Cincinnati, Cincinnati, Ohio

break

9:55-10:30 a.m. | American Ballroom Foyer

Plenary Session 5: KRAS Cell Biology

10:30-11:50 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, Nebraska

  • 10:35 a.m. | Targeting KRAS for pancreatic cancer treatment
    Channing Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
  • 11 a.m. | Elucidation of metabolic resistance mechanisms to RAS inhibition
    Kirsten Bryant, University of North Carolina, Chapel Hill, North Carolina
  • 11:25 a.m. | RAS mutation tropism: Insight into tumor initation
    Christopher M. Counter, Duke University School of Medicine, Durham, North Carolina

lunch on own

11:50 a.m.-2:30 p.m.

Plenary Session 6: Early Detection and Interception of Precursor Lesions

2:30-4:05 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Peter J. Allen, Duke University School of Medicine, Durham, North Carolina

  • 2:35 p.m. | Title to be announced
    Peter J. Allen
  • 3 p.m. | Multimodal tools for noninvasive cancer monitoring
    Erica D. Pratt, Boston University, Boston, Massachusetts
  • 3:25 p.m. | Improving pancreatic cancer early detection using a tumor marker gene test
    Michael G. Goggins, Johns Hopkins University, Baltimore, Maryland
  • 3:55 p.m. | Genomic and transcriptomic characterization of pancreatic cancer patients on the PASS-01 trial*
    Grainne O’Kane, Princess Margaret Cancer Centre, Toronto, ON, Canada
  • 4:05 p.m. | Tracing pancreatic cancer through space
    Eileen Carpenter, University of Michigan, Ann Arbor, Michigan

Break

4:15-4:35 p.m. | American Ballroom Foyer

Plenary Session 7: tumor cell biology

4:35-6 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, Nebraska

  • 4:40 p.m. | Syndecan 1 is a therapeutic target for KRAS-driven pancreatic cancer
    Wantong Yao, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 5:10 p.m. Stress-induced O-glycans drive immunosuppression in pancreatic cancer
    Tobiloba Oni, Whitehead Institute, Cambridge, Massachusetts
  • 5:35 p.m. | Metabolic adaptations to autophagy inhibition
    Christina Towers, The Salk Institute for Biological Studies, La Jolla, California

lightning presentation session c

6-6:15 p.m. | American Ballroom Center & North | CME Eligible

  • 6 p.m. | Introduction of Lighting Presentation Speakers
    Peter J. Allen, Duke University School of Medicine, Durham, North Carolina
  • 6:05 p.m. | RNF43 loss induces an IRE1-dependent metabolic reprogramming in pancreatic cystic neoplasms*
    Akiko Sagara, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 6:08 p.m. | Cell polarity proteins as novel regulators of macropinocytosis*
    Guillem Lambies Barjau, Sanford Burnham Prebys Medical Discovery, Institute, La Jolla, California
  • 6:11 p.m. | Hepcidin-mediated iron sequestration limits CD8+ tumor infiltrating lymphocytes in pancreas adenocarcinoma*
    Joshua Schoenfeld, Memorial Sloan Kettering Cancer Center, New York, New York

poster session c/reception

6:30-9 p.m. | American Ballroom South

Wednesday, September 18

CONTINENTAL BREAKFAST

7-8 a.m. | Essex Ballroom (3rd Floor)

Plenary Session 8: plasticity

8-9:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, Massachusetts

  • 8 a.m. | TGFb in pancreatic cancer
    Stephanie K. Dougan
  • 8:25 a.m. | Regulation of tumor and stromal cell plasticity by metabolic stress
    Cosimo Commisso, Sanford Burnham Prebys, San Diego, California
  • 8:50 a.m. | The role of methionine oxidation in pancreatic tumorigenesis
    Christine Chio, Columbia University, New York, New York
  • 9:15 a.m. | PDAC proteomic subtype specification through the lens of racial health disparities
    Nicholas T. Woods, University of Nebraska Medical Center, Omaha, Nebraska
  • 9:40 a.m. | Temporal stability and chemotherapy responsiveness of classical and basal transcriptional subtypes of pancreatic cancer*
    Harshabad Singh, Dana-Farber Cancer Institute, Boston, Massachusetts

break

9:55-10:15 a.m. | American Ballroom Foyer

Plenary Session 9: metabolism

10:15-11:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Alec C. Kimmelman, NYU Langone Health, New York, New York

  • 10:20 a.m. | Identifying metabolic dependencies in pancreatic cancer
    Alec C. Kimmelman
  • 10:45 a.m. | Spatiotemporal metabolic networks in pancreatic cancer and associated cachexia
    Nada Kalaany, Harvard Medical School / Boston Children’s Hospital, Boston, Massachusetts
  • 11:10 a.m. | Targeting lipid metabolism in pancreatic cancer
    Costas A. Lyssiotis, University of Michigan Medical School, Ann Arbor, Michigan
  • 11:35 a.m. | Metabolic competition in pancreatic tumor microenvironment regulates innate immune responses
    Kamiya Mehla, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

debate: Have We Learned Anything from the KRAS Inhibitors That We Didn’t Already Know from Mice?

12-12:45 p.m. | American Ballroom Center & North | CME Eligible

Moderator: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, Nebraska

  • Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Marina Pasca Di Magliano, University of Michigan, Ann Arbor, Michigan

Departure

12:45 p.m.